The combination of PP242, a mTORC1 inhibitor, in combination with GLS inhibition (compound 968) in glioblastoma blocked tumor growth in tumor-bearing mice demonstrating that GLS inhibition reverses mTORC1- targeted therapy resistance [280]. The gene discussed is GLS; the disease is glioblastoma.